Análisis Argos
AMGN
AMGNCara1 señal de riesgo
Amgen Inc. · Healthcare
US$ 393.10
precio al 2026-07-28
Valor justo Argos*
US$ 262–295
vs. su valor justo
34% por encima
Score Argos
53/100
LA RESPUESTA
El mercado le pide crezca 14.6% al año — más de lo que ha demostrado (6%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Las ganancias crecieron 89% el último año.
✓Retorno sobre el capital alto (17%).
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
!Altman Z'' en zona roja (0.26)
VALOR2/6FUTURO2/6PASADO5/6SALUD1/6DIVIDENDO3/6
El Iris de calidad
VALOR2/6FUTURO2/6PASADO5/6SALUD1/6DIVIDENDO3/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance frágil
DividendoRetorno al accionista moderado
Score Argos53de 100Cara
Ingresos▲10%
US$ 36.7 B
Margen operativo▲34%
29.1%
Flujo de caja libre▼22%
US$ 8.1 B
Deuda neta
US$ 45.5 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 212.2B
P/E27.5x
EV/EBITDA16.3x
FCF yield3.8%
ROIC16.9%
Margen operativo29.1%
Crecim. ingresos+9.9%/año
Piotroski F8/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

247wallst.com · 9 jul
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
fool.com · 7 jul
How Safe Is Amgen's Dividend?
Near-term headwinds could sink the stock, but there is more to the story.
247wallst.com · 7 jul
Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
zacks.com · 6 jul
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.
fool.com · 6 jul
The Dow Couldn't Keep Up With Chip Stocks on Monday
Broadcom's Apple deal and AMD's self-driving ambitions powered the Nasdaq higher on Monday while the Dow spun its wheels.
zacks.com · 6 jul
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
reuters.com · 1 jul
Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel
A federal judge on Wednesday blocked Colorado ​from capping the price of Amgen's blockbuster arthritis drug Enbrel, a first-of-its-kind ‌move by a U.S. state.
zacks.com · 1 jul
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.